American Journal of Kidney Diseases
Volume 52, Issue 6, Supplement 1 , Pages S21-S28 , December 2008

Challenge of Effectively Using Erythropoiesis-Stimulating Agents and Intravenous Iron

  • Toros Kapoian, MD

      Affiliations

    • Corresponding Author InformationAddress correspondence to Toros Kapoian, MD, Department of Medicine/Nephrology, UMDNJ–Robert Wood Johnson Medical School, 1 Robert Wood Johnson Pl, MEB-412B, New Brunswick, NJ 08903

References 

  1. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584–590
  2. Drüeke TB, Locatelli F, Clyne N, et al. CREATE Investigators Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–2084
  3. Singh AK, Szczech L, Tang KL, et al. CHOIR Investigators Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–2098
  4. US Food and Drug Administration and Center for Drug Evaluation and Research. Information for Healthcare Professionals: Erythropoiesis Stimulating Agents (ESA). http://www.fda.gov/cder/drug/InfoSheets/HCP/RHE2007HCP.htmAccessed February 25, 2008
  5. National Kidney Foundation. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease, 2007 Update of Hemoglobin Target. Am J Kidney Dis. 2007;50:471–530
  6. Centers for Medicare & Medicaid Services. CMS Manual System (Pub 100-04 Medicare Claims Processing. Transmittal 1307. Change Request 5700. 7-20-2007). http://www.cms.hhs.gov/Transmittals/Downloads/R1307CP.pdfAccessed January 3, 2008
  7. US Renal Data System. USRDS 2007 Annual Data Report. Bethesda, MD: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2007;
  8. FDA. Aranesp (darbepoetin alfa) for injection: Prescribing information. Silver Spring, MD: US Food and Drug Administration (USFDA); March 2008;
  9. FDA. Procrit (Epoetin alfa) for injection: Prescribing information. Silver Spring, MD: US Food and Drug Administration (USFDA); March 2008;
  10. Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int. 2005;68:1337–1343
  11. Yang W, Israni RK, Brunelli SM, Joffe MM, Fishbane S, Feldman HI. Hemoglobin variability and mortality in ESRD. J Am Soc Nephrol. 2007;18:3164–3170
  12. Ebben JP, Gilbertson DT, Foley RN, Collins AJ. Hemoglobin level variability: Associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol. 2006;1:1205–1210
  13. Gilbertson DT, Ebben JP, Foley RN, Weinhandl ED, Bradbury BD, Collins AJ. Hemoglobin level variability: Associations with mortality. Clin J Am Soc Nephrol. 2008;3:133–138
  14. Portolés J, López-Gómez JM, Aljama P. A prospective multicentre study of the role of anaemia as a risk factor in haemodialysis patients: The MAR Study. Nephrol Dial Transplant. 2007;22:500–507
  15. National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis. 2006;47(suppl 3):S11–S145
  16. Fishbane S, Besarab A. Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets. Clin J Am Soc Nephrol. 2007;2:1274–1282
  17. Petroff S. Evaluating traditional iron measures and exploring new options for patients on hemodialysis. Nephrol Nurs J. 2005;32:65–73
  18. National Kidney Foundation. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2000. Am J Kidney Dis. 2001;37(suppl 1):S182–S238
  19. Gastaldello K, Vereerstraeten A, Nzame-Nze T, et al. Resistance to erythropoietin in iron-overloaded haemodialysis patients can be overcome by ascorbic acid administration. Nephrol Dial Transplant. 1995;10(suppl 6):S44–S47
  20. Tarng DC, Wei YH, Huang TP, et al. Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia. Kidney Int. 1999;55:2477–2486
  21. Attallah N, Osman-Malik Y, Frinak S, Besarab A. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia. Am J Kidney Dis. 2006;47:644–654
  22. Locatelli F, Aljama P, Barany P, et al. Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004;19(Suppl 2):ii1–ii47
  23. Lin JL, Chang MY, Tan DT, Leu ML. Short-term small-dose intravenous iron trial to detect functional iron deficiency in dialysis patients. Am J Nephrol. 2001;21:91–97
  24. Wish JB. Assessing iron status: Beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol. 2006;1(suppl 1):S4–S8
  25. Regidor DL, Kopple JD, Kovesdy CP, et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol. 2006;17:1181–1191
  26. US Food and Drug Administration and Center for Drug Evaluation and Research. Questions and Answers for Erythropoiesis-Stimulating Agents (ESAs) Labeling Changes. http://www.fda.gov/CDER/drug/infopage/RHE/qa2007.htmAccessed February 25, 2008
  27. Centers for Medicare & Medicaid Services. 2005 Annual Report, End-Stage Renal Disease Clinical Performance Measures Project. Baltimore, MD: Department of Health and Human Services, Centers for Medicare & Medicaid Services, Office of Clinical Standards and Quality; 2005;
  28. Coyne DW, Kapoian T, Suki W, et al. DRIVE Study Group Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol. 2007;18:975–984
  29. Kapoian T, O'Mara NB, Singh AK, et al. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol. 2008;19:372–379
  30. Warady BA, Zobrist RH, Wu J, Finan E Ferrlecit Pediatric Study Group. Sodium ferric gluconate complex therapy in anemic children on hemodialysis. Pediatr Nephrol. 2005;20:1320–1327
  31. Nissenson AR, Lindsay RM, Swan S, Seligman P, Strobos J. Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American clinical trial. Am J Kidney Dis. 1999;33:471–482

 This article was published as part of a supplement sponsored by an educational grant from Watson Pharmaceuticals.

PII: S0272-6386(08)01300-0

doi: 10.1053/j.ajkd.2008.09.004

American Journal of Kidney Diseases
Volume 52, Issue 6, Supplement 1 , Pages S21-S28 , December 2008

Article Tools

* Image Usage & Resolution